MiSight® 1 day Six-Year Study Findings Verified, Companion Video Offers Highlights for ECPs
A new peer-reviewed paper has further validated the myopia control efficacy of CooperVision’s innovative MiSight® 1 day contact lenses. Published in Ophthalmic and Physiological Optics, the journal of the UK College of Optometrists, Six-Year Cumulative Treatment Effect and Treatment Efficacy of a Dual Focus Myopia Control Contact Lens (Chamberlain P, et al) details findings and insights from the ground-breaking study—the longest investigation of its kind. The paper is available via open access here.
In addition, the company has released a companion video interview with two of the paper’s co-authors and CooperVision R&D leaders: Senior Director of Research Programs Paul Chamberlain, BSc (Hons) and Research Fellow Arthur Bradley, PhD. Hosted by Myopia Profile’s Kate Gifford, PhD and Paul Gifford, PhD, it describes the study methodologies, outcomes, and clinical applications.
“We remain committed to provide eye care professionals with high quality evidence to answer important questions on the long-term impact of myopia management with MiSight® 1 day” said Chamberlain, CooperVision. “The rigorous, multi-center study design, unequaled investigation timeframe, and clear outcomes have strengthened prescribing confidence for this unique, effective optical intervention to slow the progression of myopia. This publication will further reinforce those evidence-based behaviors, as the global eye care community collectively addresses the childhood myopia epidemic.”
The paper describes that in the absence of a second phase control group for ethical reasons, prior myopia progression, emmetropic eye growth, and delay in time to progress analysis methods can be used to estimate myopia control efficacy. MiSight® 1 day slowed eye growth to less than half that observed in untreated children, paralleling modelled rates of emmetropic eye growth. Moreover, when myopic children begin treatment with MiSight® 1 day between the ages of 8-12, the probability of > 0.3mm eye growth occurring within one to three years decreased by 95%.
The paper also confirms the value of pursuing myopia control treatment for young children using MiSight® 1 day. Early intervention provides opportunity for greater myopia control potential, which may help reduce reliance on vision correction, limit changes in prescriptions between appointment visits in support of developmental and educational milestones, lessening myopia’s impact on future ocular health.
Now prescribed in more than 30 countries, CooperVision’s MiSight® 1 day is the first and only soft contact lens approved by the FDA* to both correct vision and slow the progression of myopia in children aged 8-12 at the initiation of treatment. Additionally, it was the first Chinese NMPA-approved soft contact lens with an indication relating to slowing the progression of axial length in patients who at initiation are 8-12 years old and have a refraction of -0.75 D to -4.00 D with ≤ 0.75 diopters of astigmatism. It also has the CE mark designation. The company also offers a range of orthokeratology contact lens designs and spectacle lenses with Diffusion Optics Technology™ for myopia management.
Click HERE for the full press release.
For more related content on Optik Now, click HERE.